From Yahoo Finance: 2025-06-13 12:19:00

AstraZeneca has signed a $5.2bn deal with CSPC Pharmaceuticals to research chronic disease drug candidates, with an upfront fee of $110m and milestone payments totaling $1.62bn. The partnership aims to develop pre-clinical candidates for multiple targets, including an oral therapy for immunological diseases using CSPC’s AI-powered drug discovery platform. AstraZeneca will have exclusive rights to develop and commercialize any identified candidates worldwide. This collaboration marks AstraZeneca’s second investment in China this year, as the country continues to attract Western big pharma companies despite political tensions with the US. Transactions between US and Chinese biopharma companies hit record highs in 2024, totaling $41.5bn across big pharma.



Read more at Yahoo Finance: AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal